GamaSTAN (Immune Globulin Intramuscular) is administered by a healthcare professional only, using the intramuscular (IM) injection route. It is crucial that it is given correctly and safely.

• Administration Route: Must be given by intramuscular (IM) injection ONLY. It should never be injected intravenously (into a vein) or subcutaneously (under the skin), as this can lead to serious adverse reactions or be ineffective.
• Injection Site:
  • For adults and older children, the preferred site is the deltoid muscle (upper arm) or the anterolateral muscles of the thigh.
  • For infants and small children, the anterolateral thigh is usually the preferred site.
  • The gluteal (buttock) region should only be used if there is no alternative, due to the risk of sciatic nerve damage.
• Volume Limits: No more than 5 mL should be injected into a single muscle site at one time for adults. For children, the maximum volume per site varies by age and muscle mass. If the total dose requires more than 5 mL, it should be divided and injected into multiple separate muscle sites.
• Aseptic Technique: The injection must be performed using strict aseptic (sterile) technique to prevent infection.
• Preparation: The solution should be inspected visually before use for particulate matter and discoloration. It should be clear or slightly opalescent and colorless to pale yellow. Do not use if it is cloudy or contains particles. Do not shake.
• Timing: The timing of administration varies based on the exposure and the condition being prevented (as detailed in the “Dosage Guidelines” section).

You will receive this injection from a nurse or doctor in a clinic, hospital, or doctor’s office.

GamaSTAN works by providing a rapid influx of pre-formed antibodies into the recipient’s body. These antibodies are primarily immunoglobulin G (IgG), the most common type of antibody found in human blood.

The mechanism is as follows:

• Passive Immunization: When GamaSTAN is injected, the antibodies it contains circulate in the recipient’s bloodstream.
• Virus Neutralization: These antibodies can recognize and bind to specific viral particles (e.g., hepatitis A virus, measles virus) that the recipient may have been exposed to. By binding, the antibodies neutralize the viruses, preventing them from infecting cells or marking them for destruction by the recipient’s immune system.
• Immediate Protection: Unlike active immunization (vaccination), which takes time for the body to develop its own immune response, passive immunization provides immediate protection.
• Temporary Effect: The protection offered by GamaSTAN is temporary because the antibodies are eventually broken down and eliminated from the body. The duration of protection depends on the dose given and the specific infection, typically lasting a few weeks to months.

This immediate, passive defense is crucial in situations where a susceptible individual has been exposed to a serious virus and needs rapid protection.

Like all medications, GamaSTAN (Immune Globulin Intramuscular) can cause side effects, although most are mild and temporary. Serious reactions are rare.

Common side effects (often localized to the injection site or mild systemic reactions):

• Injection site reactions: Pain, tenderness, soreness, redness, swelling, or warmth at the injection site. These are usually mild and resolve quickly.
• Headache: A common systemic side effect.
• Malaise/Fatigue: A general feeling of discomfort, illness, or tiredness.
• Nausea or Vomiting.
• Fever or chills: Mild, temporary fever or chills can occur.

More serious, but less common, side effects that require immediate medical attention:

• Allergic Reactions (Hypersensitivity): These can range from mild skin reactions (hives, rash, itching) to severe, life-threatening anaphylactic reactions. Symptoms of a severe reaction include:
  • Difficulty breathing or wheezing.
  • Swelling of the face, lips, tongue, or throat.
  • Severe dizziness or fainting.
  • Rapid heartbeat.
  • Chest pain or tightness.
  • Sudden drop in blood pressure. These reactions can occur immediately or, rarely, hours after the injection. Individuals with a complete IgA deficiency are at higher risk of severe allergic reactions.
• Systemic Reactions: While rare for IM immune globulin, symptoms such as low blood pressure, fainting, or signs of kidney problems have been reported with immune globulin products in general.
• Transmission of Infectious Agents: Despite screening and manufacturing processes designed to reduce this risk, products made from human blood theoretically carry a remote risk of transmitting infectious agents (e.g., viruses, Creutzfeldt-Jakob disease).

Always report any new, unusual, or severe symptoms to your doctor immediately.

Several important warnings and precautions are associated with GamaSTAN (Immune Globulin Intramuscular) to ensure patient safety:

• NEVER Administer Intravenously (IV): This is the most critical warning. GamaSTAN is specifically formulated for intramuscular injection. Accidental intravenous administration can lead to severe systemic reactions, including anaphylactic shock, due to the presence of protein aggregates or complement activation.
• IgA Deficiency: GamaSTAN is contraindicated in individuals with a selective IgA deficiency who have known antibodies to IgA. Such individuals are at increased risk of severe anaphylactic reactions to human immune globulin products. Your doctor should check your IgA status if there’s any suspicion.
• Allergic Reactions: Be prepared to manage potential allergic or anaphylactic reactions. Although less common with IM than IV immune globulins, such reactions can occur. Ensure that appropriate medical treatment (e.g., epinephrine) and personnel are immediately available.
• Coagulation Disorders: Use with caution in individuals with bleeding disorders or who are taking anticoagulants, as IM injections carry a risk of hematoma formation.
• Live Virus Vaccine Interference: As detailed in the “Interactions” section, GamaSTAN can interfere with the effectiveness of live attenuated virus vaccines. Vaccinations should be appropriately timed.
• Pre-existing Medical Conditions: Caution is advised in patients with severe underlying conditions (e.g., severe kidney disease, cardiovascular disease), although systemic effects are less pronounced with IM administration compared to IV.
• Renal Function: While less directly impactful than IVIG, patients with underlying renal insufficiency should be monitored, as immune globulin products have rarely been associated with acute renal dysfunction.
• Information on Infectious Agents: Advise patients that GamaSTAN is derived from human plasma. Despite robust screening and inactivation/removal processes, a theoretical risk of transmitting infectious agents cannot be completely eliminated.

GamaSTAN works by providing a rapid influx of pre-formed antibodies into the recipient’s body. These antibodies are primarily immunoglobulin G (IgG), the most common type of antibody found in human blood.

The mechanism is as follows:

• Passive Immunization: When GamaSTAN is injected, the antibodies it contains circulate in the recipient’s bloodstream.
• Virus Neutralization: These antibodies can recognize and bind to specific viral particles (e.g., hepatitis A virus, measles virus) that the recipient may have been exposed to. By binding, the antibodies neutralize the viruses, preventing them from infecting cells or marking them for destruction by the recipient’s immune system.
• Immediate Protection: Unlike active immunization (vaccination), which takes time for the body to develop its own immune response, passive immunization provides immediate protection.
• Temporary Effect: The protection offered by GamaSTAN is temporary because the antibodies are eventually broken down and eliminated from the body. The duration of protection depends on the dose given and the specific infection, typically lasting a few weeks to months.

This immediate, passive defense is crucial in situations where a susceptible individual has been exposed to a serious virus and needs rapid protection.

The dosage of GamaSTAN (Immune Globulin Intramuscular) is determined by the patient’s body weight and the specific condition for which it is being administered. It’s crucial to follow the precise instructions from your healthcare provider.

• Hepatitis A Prophylaxis:
  • Post-Exposure: 0.02 mL/kg body weight, given as soon as possible after exposure (typically within 2 weeks).
  • Pre-Exposure (Travel to endemic areas):
    • Short-term exposure (up to 3 months): 0.02 mL/kg.
    • Longer-term exposure (3-5 months): 0.06 mL/kg.
    • Repeated doses are needed every 4-6 months for prolonged exposure.
• Measles (Rubeola) Prophylaxis:
  • Normal Susceptible Contacts: 0.25 mL/kg body weight, administered within 6 days of exposure.
  • Immunocompromised Susceptible Contacts: 0.5 mL/kg body weight (maximum 15 mL), administered within 6 days of exposure.
• Varicella (Chickenpox) Modification:
  • When Varicella-Zoster Immune Globulin (VZIG) is unavailable: 0.6 to 1.2 mL/kg body weight. Administer promptly after exposure.
• Rubella Modification:
  • For exposed pregnant women who will not consider a therapeutic abortion: 0.55 mL/kg body weight. Administer as soon as possible after exposure.
• Administration: All doses are given via intramuscular injection (IM). Large doses (over 5 mL in adults) should be divided and injected into multiple separate muscle sites.

Your healthcare provider will determine the exact dose and schedule based on your individual circumstances.

GamaSTAN (Immune Globulin Intramuscular) is a prescription-only medication (POM). It is never available over-the-counter in Pakistan or any other regulated healthcare system globally. Its strict prescription requirements are due to several crucial factors:

• Specific Medical Indications: It is used for specific post-exposure prophylaxis or disease modification in limited scenarios, requiring a confirmed exposure and assessment of patient susceptibility.
• Specialist Oversight: The decision to administer GamaSTAN, including dosage and timing, should be made by a medical professional who understands the specific infectious diseases and immune globulin therapy.
• Administration Method: It must be administered by a trained healthcare professional via intramuscular injection, as improper administration can lead to serious adverse effects.
• Risk of Allergic Reactions: While generally well-tolerated, the potential for serious allergic reactions (especially in IgA-deficient individuals) necessitates administration in a clinical setting where emergency measures can be taken.
• Interference with Vaccines: Its interaction with live virus vaccines requires careful planning and patient education by a healthcare professional.
• Blood Product: As a product derived from human blood, its use falls under strict regulatory control to ensure safety and prevent transmission of infectious agents.

Therefore, a licensed medical doctor must prescribe GamaSTAN. It will be administered to you in a clinic, hospital, or doctor’s office under medical supervision.

1. What is GamaSTAN (IGIM)?

   • GamaSTAN is a human immune globulin product given intramuscularly to provide passive antibody protection.

2. What is GamaSTAN used for?

   • It’s primarily used for post-exposure prophylaxis against certain viral infections (notably hepatitis A) and for persons at high risk when vaccine is contraindicated or immediate protection is needed.

3. How does GamaSTAN work?

   • It supplies ready-made antibodies that provide immediate, short-term immunity by neutralizing pathogens.

4. How is GamaSTAN administered?

   • Given as an intramuscular injection; dosing and number of injections depend on exposure and patient factors.

5. Who should receive GamaSTAN?

   • People exposed to hepatitis A (or other designated indications), immunocompromised patients, infants, or those for whom vaccine is unsuitable.

6. Can GamaSTAN be used instead of hepatitis A vaccine?

   • It’s used when immediate passive protection is needed or vaccine is contraindicated; vaccine is preferred for long-term immunity when possible.

7. How long does protection from GamaSTAN last?

   • Protection is temporary (weeks to months); duration depends on dose and individual factors.

8. Can GamaSTAN be given with vaccines?

   • It can interfere with live or live-attenuated vaccine responses (e.g., MMR); timing recommendations exist—consult public health guidance.

9. What are common side effects?

   • Injection-site pain, soreness, mild systemic reactions (fever, malaise); allergic reactions are possible.

10. Are there serious risks with GamaSTAN?

    • Rare risks include severe hypersensitivity/anaphylaxis and transmission of infectious agents despite screening (extremely low).

11. Can people with IgA deficiency receive GamaSTAN?

    • Use with caution; those with anti-IgA antibodies may have increased risk of reactions—consult specialist.

12. Is GamaSTAN safe during pregnancy?

    • Generally considered when benefits outweigh risks (passive antibodies can be protective); consult obstetric care.

13. Can breastfeeding individuals receive GamaSTAN?

    • Yes—immune globulins are generally compatible with breastfeeding and may provide neonatal benefit.

14. Does GamaSTAN interact with other medications?

    • No major drug–drug interactions, but it can affect responses to vaccines—see timing guidance.

15. How soon after exposure should GamaSTAN be given?

    • As soon as possible after exposure for optimal post-exposure prophylaxis; specific windows vary by disease.

16. Is testing required before receiving GamaSTAN?

    • Not usually required for prophylactic use, but clinical evaluation guides administration.

17. Can GamaSTAN be used for pre-exposure prophylaxis?

    • Rarely used for routine pre-exposure prophylaxis; specific high-risk situations may warrant consideration.

18. How is GamaSTAN stored?

    • Store refrigerated as per product labeling; do not freeze. Follow manufacturer instructions.

19. Is GamaSTAN covered by insurance?

    • Coverage varies; many insurers cover prophylaxis in approved indications—verify with payer.

20. Where can I get more information in an emergency?

    • Contact local public health authorities, hospital infection control, or the product manufacturer for guidance.